Shopping Cart
- Remove All
- Your shopping cart is currently empty
Stavudine (BMY-27857), a nucleoside reverse transcriptase inhibitor analog of thymidine, has activity against HIV.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
50 mg | $33 | In Stock | |
100 mg | $47 | In Stock | |
200 mg | $65 | In Stock | |
500 mg | $97 | In Stock | |
1 mL x 10 mM (in DMSO) | $50 | In Stock |
Description | Stavudine (BMY-27857), a nucleoside reverse transcriptase inhibitor analog of thymidine, has activity against HIV. |
In vitro | In lean mice, Stavudine (500 mg/kg/day) reduces mitochondrial DNA in the liver and muscle, inducing ketoacidosis during fasting periods. In obese mice, Stavudine (500 mg/kg/day) depletes mtDNA in White Adipose Tissue (WAT). |
In vivo | Stavudine reduces lipid content and influences the expression of lipid metabolism markers, such as C/EBPα, peroxisome proliferator-activated receptor γ, adipocyte lipid-binding protein 2, fatty acid synthase, and acetyl-CoA carboxylase. In 3T3-F442A cells, Stavudine induces apoptosis and reduces both lipid content and viability in 3T3-L1 adipocytes. Furthermore, in peripheral blood mononuclear cells (PBMC), Stavudine inhibits the production of p24 antigen by HIV-1, with an effective dose range of 0.04 μM to 0.2 μM (ED50 = 0.04 μM-0.2 μM). |
Alias | Sanilvudine, NSC 163661, d4T, BMY-27857 |
Molecular Weight | 224.21 |
Formula | C10H12N2O4 |
Cas No. | 3056-17-5 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 50 mg/mL (223.01 mM) H2O: 22.4 mg/mL (100 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.